Top 5 Most Read Full Genomic Profiling Articles of 2021

The 5 most-read full genomic profiling articles of 2021 on mainly focused on the use of liquid biopsy and how biomarkers can offer providers new ways to help predict related outcomes. treatment and identify therapeutic targets.

In 2021, the 5 most-read full genomic profiling (CGP) articles of 2021 on primarily focused on the use of genomic profiling as a means of identifying possible treatment-related outcomes and targetable biomarkers. Two articles discussed how liquid biopsy can be used to improve providers’ ability to make treatment decisions for patients with non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).

The year also brought news of Foundation Medicine’s partnership with Epic to streamline vendor decision-making capabilities by integrating CGP and other testing services in a central location.

5. Liquid biopsy of cerebrospinal fluid may improve therapeutic considerations in NSCLC

The researchers found that the unique genomic variations found in cerebrospinal fluid could be used as a fluid biopsy to safely and effectively improve the ability of providers to make decisions about treating patients with NSCLC with leptomeningeal metastasis. The results may represent a better surrogate endpoint for molecular analysis in patients with NSCLC whose tumor tissue is not available.

Read the entire article.

4. Study: Serial liquid biopsy may be useful to identify RAS Genetic mutations in mCRC

Serial liquid biopsies could serve as a useful tool to identify changes in the mutational state of genes in the RAS according to the results of the study. The retrospective analysis supported the notion that mCRC is an evolving condition and that mutational changes in RAS genes can be induced by antiangiogenic therapy in mCRC patients.

Read the entire article.

3. Study reveals biomarkers predictive of toxicity and efficacy of chemoradiation in NSCLC

Using CGP, several predictive biomarkers could be exploited to predict the efficacy and toxicity of chemoradiotherapy in patients with NSCLC, according to these September results. The results also showed that progression-free survival and overall survival were associated with some of the identified genes and that chemoradiation was limited by individual variations in radiosensitivity and the risk of radiation-induced chest toxicity.

Read the entire article.

2. Pathologists Discuss Mutations and Workable Tests in Metastatic Breast Cancer

Diagnostic tools and options for patients with recurrent or advanced metastatic breast cancer were presented at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors. Kimberly H Allison, MD, director of breast pathology at Stanford Cancer Institute (SCI), and Melinda L Telli, MD, director of the breast cancer program at SCI, used real-life examples to demonstrate how genetic profiling of these cancers could give rise to an actionable, targetable biomarker.

Read the entire article.

1. Foundation Medicine, Epic partner on access to genomic profiling in EHRs

Foundation Medicine has announced a partnership to integrate its CGP and other testing services with Epic’s electronic health record (EHR) system, which allows providers to electronically order genomic tests for patients within the Epic network. The optimized integration will support oncology practices, academic medical centers and other health systems by consolidating clinical and genetic information in a single location, enabling providers to make more streamlined clinical decisions.

Read the entire article.

About Hector Hedgepeth

Check Also

“I Am Gen Z”: How the younger generation braves technological submersion

Technology has always been a double-edged sword. But Gen Z has been forced to wield …